Azelis stock sits 2.46 percent below its 52-week high

Published on 10/09/2026 at 13:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Azelis stock costs EUR 12.29 on October 9, 2026 after EUR 12.07, plus 1.82 percent. First-half revenue rose 3.20 percent to EUR 2.20 billion.

Key points in brief

Azelis stock was trading at EUR 12.29 at Lang & Schwarz on October 9, 2026, up 1.82 percent versus EUR 12.07.
The price stood 2.46 percent below the EUR 12.60 52-week high listed on October 2, 2026.
First-half 2026 revenue rose 3.20 percent to EUR 2.20 billion, while adjusted EBITDA reached EUR 233.00 million.
Azelis operates as a specialty chemicals and food ingredients distributor listed on Euronext Brussels under AZE.

Azelis, BE0974400328, Illustration mit AI erstellt.

Azelis stock was trading at EUR 12.29 at Lang & Schwarz on October 9, 2026 at 1:11 p.m. CEST, up 1.82 percent versus the prior close of EUR 12.07. The price stood 2.46 percent below the EUR 12.60 52-week high listed by finanzen.at on October 2, 2026.

Stock stays near yearly high

The latest euro quote puts Azelis 2.46 percent below its documented yearly peak, calculated from EUR 12.29 and EUR 12.60. That distance leaves the share close to its upper trading boundary while the current session gain remains below the 2.00 percent threshold for a main-clause price move.

Azelis is listed on Euronext Brussels under ticker AZE, and its business combines specialty chemical distribution with food and nutrition ingredients. The company serves Life Sciences and Industrial Chemicals markets, including personal care, pharmaceuticals, coatings, adhesives and sealants.

What supports the valuation?

The latest reported operating period provides the clearest numerical support. In its July 30, 2026 first-half earnings presentation, Yahoo Finance reported revenue of EUR 2.20 billion, up 3.20 percent year on year in constant currency. Adjusted EBITDA was EUR 233.00 million, an increase of 2.60 percent, with an adjusted EBITDA margin of 10.70 percent.

The same presentation showed adjusted EBITDA growth of 12.00 percent after normalization for one-off items and foreign-exchange effects. Free cash flow reached EUR 122.00 million in the first half, while net debt stood at EUR 1.60 billion at June 30, 2026.

Three dated milestones

On June 30, 2026, the reporting period ended with revenue of EUR 2.20 billion and adjusted EBITDA of EUR 233.00 million. On July 30, 2026, Azelis presented those first-half figures and described positive organic revenue growth in the second quarter, according to Yahoo Finance. On October 6, 2026, UBS held 7,342,752 combined voting rights and equivalent instruments, equal to 3.01 percent of Azelis, according to Business Wire in a disclosure dated October 8, 2026.

Price remains the key marker

For investors, the combination of a 1.82 percent daily gain, a 2.46 percent gap to the yearly high and 3.20 percent first-half revenue growth gives the stock a clear numerical framework. The next assessment point is whether organic growth and cash conversion continue to improve while leverage declines from EUR 1.60 billion of net debt.

The further course of trading is shown by the continuously updated real-time quote of Azelis stock.